VEGF-Trap Modulates Retinal Inflammation in the Murine Oxygen-Induced Retinopathy (OIR) Model
Anti-Vascular Endothelial Growth Factor (VEGF) agents are the first-line treatment for retinal neovascular diseases, which represent the most prevalent causes of acquired vision loss world-wide. VEGF-Trap (Aflibercept, AFL), a recombinant decoy receptor recognizing ligands of both VEGFR-1 and -2, wa...
Main Authors: | Jesús Eduardo Rojo Arias, Vanessa Elisabeth Englmaier, József Jászai |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/2/201 |
Similar Items
-
Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity
by: Vasumathy Vedantham
Published: (2019-01-01) -
Effects of Shuangdanmingmu capsule on retinal vascular morphology and VEGF expression in rats with diabetic retinopathy
by: Yu-Hui Qin, et al.
Published: (2015-01-01) -
Targeting VEGF in canine oxygen-induced retinopathy - a model for human retinopathy of prematurity
by: McLeod DS, et al.
Published: (2016-05-01) -
Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
by: Julia de Lima Farah, et al.
Published: (2018-10-01) -
The Impact of Hyperglycemia on VEGF Secretion in Retinal Endothelial Cells
by: Caprnda Martin, et al.
Published: (2017-06-01)